About City of Hope
City of Hope is an independent biomedical research and treatment organization for cancer, diabetes and other life-threatening diseases.
Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and their health care partners by providing access to City of Hope’s specialized cancer expertise.
A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.
City of Hope’s commitment to Diversity, Equity and Inclusion
We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all of our communities. Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds and experiences to our work -- and that our teams align with the people we serve in order to build trust and understanding. We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds and perspectives; this is reflected in our work and represented in our people.
Dr. Alexey Danilov’s research is focused on the mechanisms of lymphomagenesis and identification of novel therapeutic targets in B-cell lymphoma and other cancers. Following our recent laboratory discoveries, we also explore the immunomodulatory effects of novel targeted agents and aim to harness their potential to enhance the efficacy of immunotherapy and novel cellular therapies.
We are looking for a Postdoc to advance one of the following areas of interest in our laboratory:
- immunomodulatory effects of targeted agents and mechanism-driven approaches to enhance efficacy of immune and cellular therapies;
- oncogenic mechanisms of transcriptional cyclin-dependent kinases.
Dr. Danilov's group coordinates a number of Phase I/II clinical trials, thus presenting an opportunity to verify the pre-clinical hypotheses in the clinical setting and conferring immediate relevance to pre-clinical investigations.
This position is created to continue research studies currently funded by the NCI R01, the Leukemia and Lymphoma Society Translational Research Program Award, MCL Research Initiative and Scholar Award. The project will match the candidate’s interests and experience.
Highly-motivated candidates with expertise in molecular biology, immunology, biochemistry and in vivo models who are interested in a career in oncology basic/translational research will be most competitive for this position.
The individual will be responsible for leading a collaborative research project focused on extrinsic mechanisms and drug resistance. Expertise with molecular biology and in vivo models will be required for this project. Additional responsibilities include, but are not limited to: maintaining a high level of professional expertise in the field; supervising and providing guidance and mentorship to other researchers within the laboratory; designing and directing or executing experiments; and establishing laboratory procedures and systems that enforce and maintain a high level of organization in the lab. The individual should have demonstrated success in leading, managing and participating in collaborative projects and a distinguished record of scientific and technical accomplishments
Basic education, experience and skills required for consideration:
The individual will have at least 3 years of post-graduate research experience in the relevant field. They are likely to have deep expertise in a singular area of focus but may also have worked as boundary spanners across multiple fields. Achieving this position requires that the researcher has demonstrated a satisfactory track record of scholarly activity including high-quality peer-reviewed publications. In order to maintain successful track record and show potential of growth, the individual must be actively engaged in publishing high-quality manuscripts, the development and submission of grant/funding proposals and leading projects that are aligned with the lab’s focus area.
Follows established City of Hope and department policies, procedures, objectives, performance improvement, attendance, safety, environmental, and infection control guidelines, including adherence to the workplace Code of Conduct and Compliance Plan. Practices a high level of integrity and honesty in maintaining confidentiality.
Performs other related duties as assigned or requested.
- Doctoral degree in relevant field and 3-5 years of relevant post-doctoral work experience. Five or more years in a research position, including at least 4 years of supervisory and project management experience.
- Expertise in cancer biology, molecular/hematopoiesis, and genomics required. Experience with murine leukemia, hematopoiesis, and in FACS based methods, biochemistry, and molecular biology strongly preferred
- Proficient with computers specifically MS Office (which includes, Excel, Access, Word and PowerPoint) and statistical analysis software
- Strong publication record
- Experience handling chemical and biologically hazardous materials.
- Knowledge of policy and regulations applicable to the laboratory, including but not limited to safety, animal and radiation.
- Technical proficiency, scientific creativity collaborative ability, and independent thinker
- Experience with drug sensitivity/synergy analyses preferred
As a condition of employment, City of Hope requires staff to comply with all state and federal vaccination mandates.
City of Hope is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color national origin, sex, age, status as a protected veteran, or status as a qualified individual with disability.
City of Hope is a community of people characterized by our diversity of thought, background and approach, but tied together by our commitment to care for and cure those with cancer and other life-threatening diseases. The innovation that our diversity produces in the areas of research, treatment, philanthropy and education has made us national leaders in this fight. Our unique and diverse workforce provides us the ability to understand our patients' needs, deliver compassionate care and continue the quest for a cure for life-threatening diseases. At City of Hope, diversity and inclusion is a core value at the heart of our mission. We strive to create an inclusive workplace environment that engages all of our employees and provides them with opportunities to develop and grow, both personally and professionally. Each day brings an opportunity to strengthen our work, leverage our different perspectives and improve our patients’ experiences by learning from others. Diversity and inclusion is about much more than policies and campaigns. It is an integral part of who we are as an institution, how we operate and how we see our future.